| scholarly article | Q13442814 |
| P2093 | author name string | P M van Hagen | |
| A A H J Thiadens | |||
| W A Dik | |||
| J A M van Laar | |||
| M W J Schreurs | |||
| P L A van Daele | |||
| M A W Hermans | |||
| M E J van Velthoven | |||
| R W A M Kuijpers | |||
| T O Missotten | |||
| P van Biezen | |||
| V A S H Dalm | |||
| K van Bilsen | |||
| Laixi Xue | |||
| P2860 | cites work | Infliximab Biosimilars in the Age of Personalized Medicine | Q88964917 |
| Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study | Q89280609 | ||
| The use of biologic agents in the management of uveitis | Q90734396 | ||
| Biologics and immunoglobulins in the treatment of pyoderma gangrenosum - analysis of 52 patients | Q90790372 | ||
| Anti-tumor necrosis factor agents in sarcoidosis: A systematic review of efficacy and safety | Q93181141 | ||
| Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis | Q24245033 | ||
| Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease | Q24247745 | ||
| Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data | Q31019795 | ||
| Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents | Q33915940 | ||
| Infliximab for the treatment of rheumatoid arthritis | Q34758388 | ||
| The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries | Q36059239 | ||
| The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease | Q36150080 | ||
| Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study | Q36485893 | ||
| Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution | Q36778450 | ||
| A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study | Q37206628 | ||
| A systematic review of the off-label use of biological therapies in systemic autoimmune diseases | Q37326300 | ||
| Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study | Q37616966 | ||
| Development of an activity disease score in patients with uveitis (UVEDAI). | Q37709990 | ||
| A review of CT-P13: an infliximab biosimilar | Q38203821 | ||
| Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®. | Q38699354 | ||
| Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial | Q38787053 | ||
| Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis | Q42603341 | ||
| Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry | Q42846272 | ||
| Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha | Q45247247 | ||
| Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK. | Q47614624 | ||
| The Behcet's disease activity index | Q47724172 | ||
| Infliximab for uveitis of Behçet's syndrome: a trend for earlier initiation | Q49927881 | ||
| The RAND 36-Item Health Survey 1.0. | Q53676093 | ||
| Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial | Q81059776 | ||
| Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab | Q81158279 | ||
| Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease | Q82502428 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 418 | |
| P577 | publication date | 2020-08-06 | |
| P1433 | published in | Frontiers in Medicine | Q27726181 |
| P1476 | title | Are Patients at Risk for Recurrent Disease Activity After Switching From Remicade® to Remsima®? An Observational Study | |
| P478 | volume | 7 |
Search more.